Knight Therapeutics Inc. ( OTCPK:KHTRF) Q2 2025 Earnings Conference Call August 7, 2025 8:30 AM ET Amal Khouri - Chief Business Officer Arvind Utchanah - Chief Financial Officer Samira Sakhia - ...

Detailed price information for Knight Therapeutics Inc (GUD-T) from The Globe and Mail including charting and trades.

She recommended following the “20-20-20 Rule” for preventing and relieving digital eye strain. The method involves taking a ...

Beginning in Q3 2026, the TTM revenue covenant will be $115 million and will remain at that level for all subsequent quarters through the maturity of the debt. In consideration for this fifth ...

(Nasdaq: GILD) announced today its second quarter 2025 results of operations. "This was a very successful second quarter for Gilead, including the FDA approval for Yeztugo as the world’s first ...

LOQTORZI net revenue was $10.0 million, a 36% increase over Q1 2025 – – Data readouts for CHS-114 and casdozokitug on track for 1H 2026 ...

Audifort is a plant-based hearing support supplement developed to tackle some of the most common auditory issues, such as ...

Data from Phase 1 clinical trial of ATH-1105 in healthy volunteers showed a favorable safety and tolerability profile; dose ...

Investigational new drug (IND) application cleared by the United States Food and Drug Administration (FDA) for ZW251 with ...

RICHMOND, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported recent business highlights and second quarter 2025 financial ...

Collaboration revenue from our Kyowa Kirin partnership for the second quarter of 2025 was $15.3 million, compared to no revenue for the second quarter of 2024. Research and development expenses for ...

He recently had the first of two six-hour procedures at Manning Family Children's Hospital to collect his stem cells in order to edit them.